Tiburio named to BioSpace’s NextGen Class of 2020

Tiburio named to BioSpace’s NextGen Class of 2020

January 6, 2020

Tiburio Therapeutics was included in BioSpace’s annually curated NextGen Bio Class, which showcases twenty top life sciences companies in North America formed since 2018 that are already making an impact in the industry. Since our launch in 2020, we at Tiburio are proud of our commitment to develop pharmaceutical treatment options for patients living rare neuroendocrine disease. We are honored to join BioSpace’s NextGen Bio Class of 2020, and we congratulate this year’s other honorees!

Read BioSpace’s full announcement here.